Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Jan 14;38(3):212-215.
doi: 10.1093/eurheartj/ehw324.

Cardiac cell-derived exosomes: changing face of regenerative biology

Raj Kishore  1   2 , Mohsin Khan  1
Affiliations
Editorial

Cardiac cell-derived exosomes: changing face of regenerative biology

Raj Kishore et al. Eur Heart J. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Exosome therapy recapitulates the benefits of cell therapy. CDC derived exosomes are generated by inward budding of endosomal membranes and accumulate in multivesicular bodies. They are released into extracellular space following the fusion of the endosomal compartment with the plasma membrane. Their cargo consists mainly of proteins and nucleic acids, with the greatest abundance and variety presented by miRNA and mRNA. Delivery of CDC exosomes to heart after injury recapitulates cardiac structural and functional effects, angiogenesis and immune modulation as seen by cell therapy.
Figure 2
Figure 2
Comparative assessment of associated pros and cons of cell therapy vs. exosome therapy. Cell therapy offers direct cell injections; the surviving cells are capable of developing into cardiac tissue and stimulate endogenous myocardial repair processes (blue boxes) but carry a number of well-documented problems (red boxes). Exosome therapy relies on exosomes derived from the cells themselves and presents a cell-free system for myocardial repair without the burdens associated with cell transplantation (blue boxes). Nevertheless, there are some limitations (red boxes) associated with exosome therapy as highlighted.
See this image and copyright information in PMC

Comment on

References

    1. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, Kasahara H, Rota M, Musso E, Urbanek K, Leri A, Kajstura J, Nadal-Ginard B, Anversa P. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003;114:763–776. - PubMed
    1. Smith RR, Barile L, Cho HC, Leppo MK, Hare JM, Messina E, Giacomello A, Abraham MR, Marban E. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 2007;115:896–908. - PubMed
    1. Bolli R, Chugh AR, D'Amario D, Loughran JH, Stoddard MF, Ikram S, Beache GM, Wagner SG, Leri A, Hosoda T, Sanada F, Elmore JB, Goichberg P, Cappetta D, Solankhi NK, Fahsah I, Rokosh DG, Slaughter MS, Kajstura J, Anversa P. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 2011;378:1847–1857. - PMC - PubMed
    1. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, Berman D, Czer LS, Marban L, Mendizabal A, Johnston PV, Russell SD, Schuleri KH, Lardo AC, Gerstenblith G, Marban E. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 2012;379:895–904. - PMC - PubMed
    1. Vrtovec B, Poglajen G, Lezaic L, Sever M, Domanovic D, Cernelc P, Socan A, Schrepfer S, Torre-Amione G, Haddad F, Wu JC. Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circ Res 2013;112:165–173. - PubMed

LinkOut - more resources